Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma

Dupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma. However, dupilumab can cause transient hypereosinophilia. In rare cases, hype...

Full description

Saved in:
Bibliographic Details
Main Authors: Agnieszka Gawlewicz-Mroczka, Marek Przybyszowski, Grażyna Bochenek, Maria Mroczka, Krzysztof Sładek
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S221300712400159X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846125465308233728
author Agnieszka Gawlewicz-Mroczka
Marek Przybyszowski
Grażyna Bochenek
Maria Mroczka
Krzysztof Sładek
author_facet Agnieszka Gawlewicz-Mroczka
Marek Przybyszowski
Grażyna Bochenek
Maria Mroczka
Krzysztof Sładek
author_sort Agnieszka Gawlewicz-Mroczka
collection DOAJ
description Dupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma. However, dupilumab can cause transient hypereosinophilia. In rare cases, hypereosinophilia can reach high levels and manifest with clinical symptoms. We present the case of a female patient who presented with hypereosinophilia of almost 5000 cells/μL accompanied by erythema nodosum during dupilumab treatment. After stopping and then restarting dupilumab, the patient developed eosinophilic pneumonia. This case highlights the need to monitor blood eosinophil count along with clinical and radiological symptoms in patients receiving dupilumab.
format Article
id doaj-art-4d2f34a5bf454071a25e07c60d218007
institution Kabale University
issn 2213-0071
language English
publishDate 2024-01-01
publisher Elsevier
record_format Article
series Respiratory Medicine Case Reports
spelling doaj-art-4d2f34a5bf454071a25e07c60d2180072024-12-13T10:57:48ZengElsevierRespiratory Medicine Case Reports2213-00712024-01-0152102136Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthmaAgnieszka Gawlewicz-Mroczka0Marek Przybyszowski1Grażyna Bochenek2Maria Mroczka3Krzysztof Sładek42nd Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Macieja Jakubowskiego 2, 30-688, Kraków, Poland2nd Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Macieja Jakubowskiego 2, 30-688, Kraków, Poland; Corresponding author. Macieja Jakubowskiego 2, 30-688, Kraków, Poland.2nd Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Macieja Jakubowskiego 2, 30-688, Kraków, PolandFaculty of Medicine, Jagiellonian University Medical College, Macieja Jakubowskiego 2, 30-688, Kraków, Poland2nd Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Macieja Jakubowskiego 2, 30-688, Kraków, PolandDupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma. However, dupilumab can cause transient hypereosinophilia. In rare cases, hypereosinophilia can reach high levels and manifest with clinical symptoms. We present the case of a female patient who presented with hypereosinophilia of almost 5000 cells/μL accompanied by erythema nodosum during dupilumab treatment. After stopping and then restarting dupilumab, the patient developed eosinophilic pneumonia. This case highlights the need to monitor blood eosinophil count along with clinical and radiological symptoms in patients receiving dupilumab.http://www.sciencedirect.com/science/article/pii/S221300712400159XAsthmaBiologicsEosinophiliaErythema nodosumDupilumab
spellingShingle Agnieszka Gawlewicz-Mroczka
Marek Przybyszowski
Grażyna Bochenek
Maria Mroczka
Krzysztof Sładek
Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
Respiratory Medicine Case Reports
Asthma
Biologics
Eosinophilia
Erythema nodosum
Dupilumab
title Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
title_full Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
title_fullStr Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
title_full_unstemmed Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
title_short Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
title_sort erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
topic Asthma
Biologics
Eosinophilia
Erythema nodosum
Dupilumab
url http://www.sciencedirect.com/science/article/pii/S221300712400159X
work_keys_str_mv AT agnieszkagawlewiczmroczka erythemanodosumfollowedbyeosinophilicpneumoniaasanadverseeffectofdupilumabtreatmentinapatientwithsevereasthma
AT marekprzybyszowski erythemanodosumfollowedbyeosinophilicpneumoniaasanadverseeffectofdupilumabtreatmentinapatientwithsevereasthma
AT grazynabochenek erythemanodosumfollowedbyeosinophilicpneumoniaasanadverseeffectofdupilumabtreatmentinapatientwithsevereasthma
AT mariamroczka erythemanodosumfollowedbyeosinophilicpneumoniaasanadverseeffectofdupilumabtreatmentinapatientwithsevereasthma
AT krzysztofsładek erythemanodosumfollowedbyeosinophilicpneumoniaasanadverseeffectofdupilumabtreatmentinapatientwithsevereasthma